reciprocal edges: 14 edges from 2 new claims

domains/health/food-noise-quiet-narrative-reframes-glp1-anhedonia-as-liberation.md

@@ -14,6 +14,8 @@ supports:
 - GLP-1 anhedonia mechanism undermines social engagement and meaning as non-clinical health determinants even while treating metabolic disease
 reweave_edges:
 - GLP-1 anhedonia mechanism undermines social engagement and meaning as non-clinical health determinants even while treating metabolic disease|supports|2026-05-06
+related:
+- glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
 ---
 
 # Cultural narrative framing 'food noise quiet' as liberation delays recognition of GLP-1 dopamine suppression harm

domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md

@@ -10,10 +10,24 @@ agent: vida
 scope: causal
 sourcer: Tzang et al. (Lancet eClinicalMedicine)
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
-related: ["glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms", "glp1-response-variability-partially-genetically-determined-glp1r-gipr-variants-predict-weight-loss-and-side-effects", "semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x"]
+related:
-reweave_edges: ["glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks|related|2026-04-09", "GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12", "Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement|challenges|2026-04-14"]
+- glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks
-supports: ["GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales"]
+- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation
-challenges: ["Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement"]
+- semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism
+- semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss
+- comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation
+- glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms
+- glp1-response-variability-partially-genetically-determined-glp1r-gipr-variants-predict-weight-loss-and-side-effects
+- semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x
+- glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
+reweave_edges:
+- glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks|related|2026-04-09
+- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12
+- Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement|challenges|2026-04-14
+supports:
+- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales
+challenges:
+- Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement
 ---
 
 # GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation

domains/health/glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant.md

@@ -18,6 +18,8 @@ related:
 - medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm
 - glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation
 - hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement
+- glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
+- glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring
 supports:
 - Cultural narrative framing 'food noise quiet' as liberation delays recognition of GLP-1 dopamine suppression harm
 reweave_edges:

domains/health/glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population.md

@@ -10,8 +10,12 @@ agent: vida
 sourced_from: health/2026-05-05-npr-glp1-eating-disorders-not-well-understood.md
 scope: structural
 sourcer: "NPR (@NPRHealth)"
-supports: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive"]
+supports:
-related: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-eating-disorder-screening-lacks-reimbursement-infrastructure-despite-identified-risk-population"]
+- glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive
+related:
+- glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge
+- glp1-eating-disorder-screening-lacks-reimbursement-infrastructure-despite-identified-risk-population
+- glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring
 ---
 
 # GLP-1 prescribing creates systematic screening gap for atypical anorexia because normal BMI masks active restrictive psychopathology

domains/health/glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap.md

@@ -10,8 +10,19 @@ agent: vida
 sourced_from: health/2025-truveta-ispor-glp1-discontinuation-reasons.md
 scope: correlational
 sourcer: Truveta Research
-supports: ["behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
+supports:
-related: ["glp-1-access-structure-inverts-need-creating-equity-paradox", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-persistence-improves-with-specialist-care-supporting-obesity-medicine-infrastructure", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-eating-disorder-risk-doubles-with-prior-mental-health-history"]
+- behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions
+related:
+- glp-1-access-structure-inverts-need-creating-equity-paradox
+- lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence
+- glp1-long-term-persistence-ceiling-14-percent-year-two
+- glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics
+- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation
+- glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap
+- glp1-persistence-improves-with-specialist-care-supporting-obesity-medicine-infrastructure
+- glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations
+- glp1-eating-disorder-risk-doubles-with-prior-mental-health-history
+- glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring
 ---
 
 # GLP-1 discontinuation is 12 percent higher among patients with psychiatric medication history creating an access-adherence trap where highest-need populations have lowest persistence

domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md

@@ -10,8 +10,21 @@ agent: vida
 sourced_from: health/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.md
 scope: structural
 sourcer: NEDA/ANAD
-supports: ["ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures"]
+supports:
-related: ["the-mental-health-supply-gap-is-widening-not-closing", "ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "neda", "anad", "glp1-eating-disorder-screening-lacks-reimbursement-infrastructure-despite-identified-risk-population", "glp1-eating-disorder-screening-protocol-scoff-plus-history-plus-behavioral-assessment-recommended-for-pre-treatment-risk-stratification", "glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population"]
+- ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures
+related:
+- the-mental-health-supply-gap-is-widening-not-closing
+- ai-telehealth-glp1-prescribing-commoditizes-at-scale-but-generates-systematic-safety-and-fraud-failures
+- glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support
+- glp1-pre-treatment-eating-disorder-screening-recommended-not-required
+- glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive
+- glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge
+- neda
+- anad
+- glp1-eating-disorder-screening-lacks-reimbursement-infrastructure-despite-identified-risk-population
+- glp1-eating-disorder-screening-protocol-scoff-plus-history-plus-behavioral-assessment-recommended-for-pre-treatment-risk-stratification
+- glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population
+- glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring
 ---
 
 # GLP-1 eating disorder screening gap is structural capacity failure not clinical knowledge deficit because professional society guidance requires tri-specialist care teams unavailable in primary care settings where most prescriptions originate

domains/health/glp1-harm-mediated-by-cultural-weight-stigma-not-pharmacology-alone.md

@@ -10,8 +10,15 @@ agent: vida
 sourced_from: health/2026-05-05-npr-glp1-eating-disorders-not-well-understood.md
 scope: causal
 sourcer: "NPR (@NPRHealth)"
-supports: ["glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway"]
+supports:
-related: ["glp1-eating-disorder-causality-expert-divergence-reflects-evidence-gap", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge"]
+- glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway
+related:
+- glp1-eating-disorder-causality-expert-divergence-reflects-evidence-gap
+- glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway
+- glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive
+- glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations
+- glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge
+- glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring
 ---
 
 # GLP-1 harm risk is mediated by cultural weight stigma and pressure rather than pharmacological properties alone

domains/health/glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations.md

@@ -18,6 +18,7 @@ related:
 - semaglutide-reduces-depression-worsening-44-percent-in-diagnosed-patients-through-glp1r-psychiatric-mechanism
 - glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive
 - GLP-1 eating disorder risk doubles with prior mental health history creating identifiable high-risk population
+- glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring
 supports:
 - WHO December 2025 GLP-1 obesity guideline contains no eating disorder screening requirement despite pharmacovigilance signal predating guideline by 18+ months
 reweave_edges:

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -10,10 +10,23 @@ agent: vida
 sourced_from: health/2026-04-23-glp1-substance-use-disorder-33-trials.md
 scope: causal
 sourcer: PubMed/ClinicalTrials.gov systematic review
-challenges: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm"]
+challenges:
-related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients"]
+- medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm
-supports: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery"]
+related:
-reweave_edges: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment|supports|2026-04-24", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery|supports|2026-04-24"]
+- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation
+- medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm
+- glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation
+- hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement
+- behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions
+- glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population
+- glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients
+- glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
+supports:
+- The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment
+- Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery
+reweave_edges:
+- The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment|supports|2026-04-24
+- Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery|supports|2026-04-24
 ---
 
 # GLP-1 receptor agonists may address multiple substance use disorders through shared mesolimbic dopamine circuit modulation with 33 clinical trials underway across alcohol opioid nicotine and cocaine use

domains/health/glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms.md

@@ -10,9 +10,20 @@ agent: vida
 scope: causal
 sourcer: "Circulation: Heart Failure (AHA Journals)"
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
-supports: ["GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport"]
+supports:
-related: ["acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef", "GLP-1 receptor agonist weight loss and side effects are partially genetically determined with GLP1R and GIPR variants predicting 6-20% weight loss range and up to 14.8-fold variation in tirzepatide-specific vomiting risk", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss", "glp1-cardiac-benefits-weight-independent-via-fibrosis-attenuation"]
+- GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport
-reweave_edges: ["acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef|related|2026-04-12", "GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport|supports|2026-04-12", "GLP-1 receptor agonist weight loss and side effects are partially genetically determined with GLP1R and GIPR variants predicting 6-20% weight loss range and up to 14.8-fold variation in tirzepatide-specific vomiting risk|related|2026-04-27"]
+related:
+- acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef
+- GLP-1 receptor agonist weight loss and side effects are partially genetically determined with GLP1R and GIPR variants predicting 6-20% weight loss range and up to 14.8-fold variation in tirzepatide-specific vomiting risk
+- glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms
+- semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism
+- semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss
+- glp1-cardiac-benefits-weight-independent-via-fibrosis-attenuation
+- glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
+reweave_edges:
+- acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef|related|2026-04-12
+- GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport|supports|2026-04-12
+- GLP-1 receptor agonist weight loss and side effects are partially genetically determined with GLP1R and GIPR variants predicting 6-20% weight loss range and up to 14.8-fold variation in tirzepatide-specific vomiting risk|related|2026-04-27
 ---
 
 # GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss

domains/health/healthcare AI creates a Jevons paradox because adding capacity to sick care induces more demand for sick care.md

@@ -10,6 +10,7 @@ related:
 - consumer willingness to pay out of pocket for AI-enhanced care is outpacing reimbursement creating a cash-pay adoption pathway that bypasses traditional payer gatekeeping
 - attractor-molochian-exhaustion
 - AI-driven GLP-1 telehealth prescribing achieves billion-dollar scale with minimal staffing but generates systematic safety and fraud failures
+- glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring
 reweave_edges:
 - AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output|related|2026-03-28
 - CMS is creating AI-specific reimbursement codes which will formalize a two-speed adoption system where proven AI applications get payment parity while experimental ones remain in cash-pay limbo|related|2026-03-28

domains/health/hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement.md

@@ -13,6 +13,7 @@ sourcer: Zhenggang Zhu, Scott M. Sternson et al., Janelia Research Campus
 related:
 - glp1-long-term-persistence-ceiling-14-percent-year-two
 - glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation
+- glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
 supports:
 - GLP-1 receptor agonists may address multiple substance use disorders through shared mesolimbic dopamine circuit modulation with 33 clinical trials underway across alcohol opioid nicotine and cocaine use
 reweave_edges:

domains/health/semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression.md

@@ -10,8 +10,17 @@ agent: vida
 sourced_from: health/2026-04-24-hendershot-jama-psychiatry-semaglutide-aud-rct.md
 scope: causal
 sourcer: Hendershot CS et al.
-supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
+supports:
-related: ["hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population"]
+- glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation
+- behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions
+related:
+- hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement
+- glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation
+- behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions
+- real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial
+- semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression
+- glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population
+- glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
 ---
 
 # Semaglutide produces large-effect-size reductions in alcohol consumption and craving through VTA dopamine reward circuit suppression